Background: Pleural effusion (PE) is a common clinical presentation of a large number of different diseases including malignant pleural mesothelioma (MPM). The approach to patients with PE is not simple and preoperative cytological examinations or even intra-operative frozen sections are often unhelpful in the differential diagnosis. This fact makes critical the management of PE, especially when MPM is suspected. Changes in the expression of microRNAs (miRNAs) have been implicated in several diseases, making miRNAs attractive biomarkers. Our aim was to determine whether a miRNA signature in plasma or in Exhaled Breath Condensate (EBC) may help to discriminate between PE related to MPM and PE of patients affected by other pleural diseases (NM).
Background: Pleural effusion (PE) is a common clinical presentation of a large number of different diseases including malignant pleural mesothelioma (MPM) . The approach to patients with PE is not simple and preoperative cytological examinations or even intra-operative frozen sections are often unhelpful in the differential diagnosis. This fact makes critical the management of PE, especially when MPM is suspected. Changes in the expression of microRNAs (miRNAs) have been implicated in several diseases, making miRNAs attractive biomarkers. Our aim was to determine whether a miRNA signature in plasma or in Exhaled Breath Condensate (EBC) may help to discriminate between PE related to MPM and PE of patients affected by other pleural diseases (NM).
Methods:
We prospectively enrolled consecutive patients with PE from suspected MPM, scheduled for thoracoscopic pleural biopsy. We recorded clinical data and definitive histological diagnosis. Exclusion criteria were age < 18 years, history of previous tumor or immunological disorder. Ethics committee approval was achieved. Written informed consent was obtained from all participants. We collected a sample of plasma and EBC from each patient before the biopsy. We screened 733 miRNAs in blood and EBC by high-throughput Open Array and compared their expression in the two groups. We used a multiple linear regression model adjusted for four principal variables (age, sex, BMI and smoking habits) to compare MPM and NM.
Results: We enrolled 32 patients; the figure below shows main clinical data.
After miRNA screening, we identified 3 miRNAs which were upregulated in EBC and 44 in plasma. In particular, in EBC: miR-378, miR-206, miR-9 with a fold-change (FC) of 1.54, 1.4, 1.23 respectively (p-value¼ 0.019, 0.04 and 0.04 respectively). The most significant in plasma was miR-489 (FC¼ 1.35, p-value¼ 0.0001).
Conclusion:
We identified a miRNAs panel that might be useful for developing a non-invasive procedure for MPM diagnosis in patients with PE. Background: Certain microRNA (miRNA)-mRNA interactions are associated with critical biologic processes in malignant pleural mesothelioma (MPM). We wondered how miRNA interact with p53 in MPM since this tumor characteristically retains the wild-type allele which is frequently bypassed by deletion of CDKN2A. This interaction among miRNA and p53 in MPM is poorly understood. Study of this interaction could provide insights on disease mechanisms and/ or novel therapeutic strategies. Methods: We retrieved several public miRNA expression MPM data sets to perform a broad survey. We combined two meta-analyses approaches to the normalized data to maximize identifying altered miRNA specific to MPM. Then miRNAs were fit into a network where they inhibited MDM2, releasing inhibition of p53, and in turn were themselves induced by p53 (p53 regulation via a reinforcing loop). Significant miRNA of this screening algorithm were confirmed by qPCR analysis in MPM tissues and cell lines. Specific miRNAs were re-expressed in MPM cells by a lentivirus system or by mimic transfection. p53-luciferase reporter system was used to assess p53 activity. MTS assay assessed cell proliferation. Apoptotic cells were detected by Annexin-V assay. Tumorigenic characteristics of MPM cells were evaluated by clonogenicity, soft agar colony formation and 3D sphere assays. Clinical relevance of these miRNA were assessed in the TCGA MPM cohort (cancergenome.nih. gov). Results: Our meta-analysis, revealed significant changes in several p53-regulated miRNAs. For example, miR-145 expression is repressed by 40% at steady state in MPM specimens (n¼38) compared to non-malignant controls (n¼21). We directly confirmed in MPM tissues a similar trend of this miRNA, while MDM2 mRNA levels were inversely higher. Next, we assessed the functional role of miR-145 in MPM cell lines with wild-type p53. Using a lentiviral expression system to sustain elevations in miR-145 levels, MDM2 transcript and protein levels were repressed, leading to increases in p53 protein and its transcriptional activity. We observed in miR-145-overexpressed MPM cell lines more apoptosis by Annexin V assay, loss of clonogenicity, growth inhibition, and attenuated tumorigenicity. To confirm that p53 can perpetuate a positive reinforcing loop inducing miR-145, we treated a panel of MPM cells with Nutlin-3a and observed coordinated increases in p53 associated with a rise in miR-145 levels. Interestingly, at least one of these miRNA was prognostic in Kaplan-Meier modeling of overall survival.
We have identified candidate miRNAs that, in part, regulate p53 activity in MPM cells. These miR-NAs function as tumor suppressors. They are candidates for therapeutic validation. Background: Pleural malignant mesothelioma(MM) is a highly aggressive tumor that mainly related to asbestos exposure. Some microRNAs (miRNAs) contribute to MM initiation and progression, but the exact mechanism remains largely unknown.
Methods: The expression of miR-30d in mesothelioma cell line NCI-H2452, chrysotile exposed MeT-5A cells and plasm of 78 human subjects with asbestos exposure was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). After NCI-H2452 cells were transfected with mimics miR-30d to overexpress mir-30d, cell viability was measured by MTS method; in vitro cell migration and invasion was measured by transwell assay and scratch assay; cell cycle and apoptosis was examined by flow cytometry; the mRNA and protein expressions of VIM, TWIST1 and CDH1 were detected by qPCR and western blotting, respectively.
Results: miR-30d was significantly downregulated not only in NCI-H2452 cells compared with MeT-5A cells, but also in chrysotile exposed MeT-5A cells compared with the negative control and in plasm of asbestos exposed subjects compared with unexposed subjects.
After transfected by miR-30d, the proliferation rate, migration rate and invasion cells of NCI-H2452 cells decreased, early apoptosis rate and total apoptosis rate increased in miR-30d transfected NCI-H2452 cells. The mRNA and protein expression of VIM and TWIST1 decreased and the mRNA expression of CDH1 increased by overexpressed miR-30d in NCI-H2452.
Conclusion: Downregulation of miR-30d is related to malignant mesothelioma and asbestos exposure. miR-30d might be a tumor-suppressor miRNA, and its downregulation might contribute to pleural MM progression and asbestos carcinogenesis. Keywords: Mesothelioma, neoplasm invasiveness, microRNA-30d (miR-30d), asbestos P3.03-012 Tumor-Infiltrating Lymphocytes, PDL-1, BAP-1, VEGFR-2 and IGF-1R Expression in Malignant Pleural Mesothelioma
